BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

South Korea's Genexine's Long-Acting Growth Hormone Meets Phase 3 Endpoint

Phase 3 clinical trial in China meets primary endpoint On track to file BLA in China in 2024 The study being conducted by Genexine’s partner in...

August 31, 2023 | News

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

The study of savolitinib is a single-arm, multi-center, open-label, Phase II registration study to evaluate the efficacy, safety and tolerability of savoli...

August 29, 2023 | News

Zhiyi Biotech Begins Phase 1 Trial of SK10 for Chemo-induced Diarrhea

SK10, the first Bacteroides fragilis-based live biotherapeutic product (LBP) obtained FDA IND approval, is also the first LBP of Next-generation probi...

August 28, 2023 | News

Agenus Focuses on Fast-Tracking BOT/BAL Program for Cancer

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources t...

August 24, 2023 | News

SK Bioscience and Vaxxas Partner for Needle-Free Typhoid Vaccine Patch

SK bioscience and Vaxxas have officially entered into a Joint Development Agreement. This collaboration is set to revolutionize vaccine delivery by devel...

August 24, 2023 | News

Lynk Pharma's LNK01001 Shows Positive Results in Ankylosing Spondylitis Phase II Trial

The study, led by Professor Xiaofeng Zeng, the director of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital and ...

August 23, 2023 | News

MGI Partners with NGeneBio to Advance Precision Medicine

This strategic partnership will enable the integration of NGeneBio's advanced diagnostic assays with MGI's high-throughput sequencing technology to acceler...

August 23, 2023 | News

CanariaBio's MAb-AR20.5 for Pancreatic Cancer Granted FDA Orphan Drug Designation

CanariaBio Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative immunotherapies for cancer, anno...

August 22, 2023 | News

3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling

3Z, holds expertise in developing genetically engineered models of central nervous system disorders, has successfully identified potential ADHD treatments ...

August 19, 2023 | News

Neurophth Begins Phase I/II Trial for Second Gene Therapy with First Patient Dosed

Neurophth is conducting a Phase I/II, multi-region, multi-center, single-arm, open-labeled, dose-finding study aimed at evaluating the safety, tole...

August 18, 2023 | News

Minghui Pharma Enrolls First Patient in Phase 3 Study for MH004 Cream in Atopic Dermatitis

The phase 3 clinical trial aims to evaluate the safety and efficacy of the investigational topical cream in a larger patient population. Leveraging the con...

August 18, 2023 | News

Parexel & Partex Unite Artificial Intelligence and Big Data to Speed Drug Discovery

Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, a...

August 16, 2023 | News

Inmagene Initiates POC Study for Extended Half-Life OX40 mAb in Atopic Dermatitis

IMG-007 is a humanized IgG1 monoclonal antibody (mAb) that specifically binds to the OX40 receptor. Its Fc region has been bioengineered, resulting in...

August 16, 2023 | News

FDA Grants Priority Review for Cefepime-Taniborbactam to Treat cUTI

Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's N...

August 16, 2023 | News

Stay Connected